Clinical Trial: Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs

Study Status: Completed
Recruit Status: Unknown status
Study Type: Observational




Official Title: Hormonal and Metabolic Responses to Oral Glucose During Somatostatin Analog Use

Brief Summary: The purpose of this study is to test the effect of long-acting somatostatin analog medications, taken by patients with acromegaly or carcinoid syndrome, on growth hormone in comparison to healthy controls who are not receiving the medication in order to see whether or not the medication makes the oral glucose test less accurate. The Oral Glucose Tolerance Test (OGTT) is a standard test to measure growth hormone secretion. By comparing GH responses in non-acromegaly subjects taking somatostatin analog treatment, the relative contribution of the medication and the underlying disease state can be analyzed.